IDEAYA Biosciences Beheer
Beheer criteriumcontroles 3/4
De CEO IDEAYA Biosciences is Yujiro Hata, benoemd in Jun2015, heeft een ambtstermijn van 9.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 6.00M, bestaande uit 10% salaris en 90% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.78% van de aandelen van het bedrijf, ter waarde $ 20.61M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2 jaar en 6 jaar.
Belangrijke informatie
Yujiro Hata
Algemeen directeur
US$6.0m
Totale compensatie
| Percentage CEO-salaris | 10.0% |
| Dienstverband CEO | 9.4yrs |
| Eigendom CEO | 0.8% |
| Management gemiddelde ambtstermijn | 2yrs |
| Gemiddelde ambtstermijn bestuur | 6yrs |
Recente managementupdates
Recent updates
Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success
Sep 20Ideaya Biosciences: Poised For Success In Bladder And Lung Cancer?
Jul 08Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality'
Jun 18Is IDEAYA Biosciences (NASDAQ:IDYA) A Risky Investment?
Feb 22
Ideaya Biosciences: A Strong Bet In Targeted Oncology
Feb 16Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week
Nov 09Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation
Oct 03IDEAYA Biosciences (NASDAQ:IDYA) Is In A Good Position To Deliver On Growth Plans
Jul 04We're Not Very Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate
Mar 10Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation
Nov 04Ideaya Biosciences: Prospects Rebound With Updated Uveal Melanoma Data
Oct 06Ideaya Biosciences slides 8.5% aftermarket on $80M stock offering
Sep 14Ideaya wins first milestone in GSK deal as cancer drug reaches clinical trials
Aug 29Analysts Have Just Cut Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Revenue Estimates By 6.2%
Aug 25IDEAYA Biosciences GAAP EPS of -$0.57 misses by $0.05, revenue of $11.34M beats by $4.75M
Aug 15IDEAYA, Amgen in clinical trial deal for small molecule cancer agent
Jul 27Ideaya: Next 6 Months Critical For Precision Oncology Biotech
Jun 16Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$178m |
| Jun 30 2024 | n/a | n/a | -US$154m |
| Mar 31 2024 | n/a | n/a | -US$129m |
| Dec 31 2023 | US$6m | US$598k | -US$113m |
| Sep 30 2023 | n/a | n/a | -US$103m |
| Jun 30 2023 | n/a | n/a | -US$74m |
| Mar 31 2023 | n/a | n/a | -US$68m |
| Dec 31 2022 | US$3m | US$570k | -US$59m |
| Sep 30 2022 | n/a | n/a | -US$53m |
| Jun 30 2022 | n/a | n/a | -US$66m |
| Mar 31 2022 | n/a | n/a | -US$55m |
| Dec 31 2021 | US$4m | US$544k | -US$50m |
| Sep 30 2021 | n/a | n/a | -US$37m |
| Jun 30 2021 | n/a | n/a | -US$30m |
| Mar 31 2021 | n/a | n/a | -US$31m |
| Dec 31 2020 | US$2m | US$510k | -US$34m |
| Sep 30 2020 | n/a | n/a | -US$40m |
| Jun 30 2020 | n/a | n/a | -US$46m |
| Mar 31 2020 | n/a | n/a | -US$44m |
| Dec 31 2019 | US$2m | US$457k | -US$42m |
| Sep 30 2019 | n/a | n/a | -US$40m |
| Jun 30 2019 | n/a | n/a | -US$42m |
| Mar 31 2019 | n/a | n/a | -US$38m |
| Dec 31 2018 | US$2m | US$420k | -US$34m |
Compensatie versus markt: De totale vergoeding ($USD 6.00M ) Yujiro } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.60M ).
Compensatie versus inkomsten: De vergoeding van Yujiro is gestegen terwijl het bedrijf verliesgevend is.
CEO
Yujiro Hata (50 yo)
9.4yrs
Tenure
US$5,995,440
Compensatie
Mr. Yujiro S. Hata serves as an Independent Director at Enanta Pharmaceuticals, Inc. since August 29, 2021. He is a Co-Founder of IDEAYA Biosciences, Inc. and has been its Chief Executive Officer, Presiden...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 9.4yrs | US$6.00m | 0.78% $ 20.6m | |
| Principal Accounting Officer | 3.8yrs | US$1.41m | 0.028% $ 745.9k | |
| Chief Scientific Officer | 3yrs | US$2.76m | 0% $ 0 | |
| Chief Medical Officer | 2yrs | US$1.81m | 0% $ 0 | |
| Chief Technology Officer | 1.8yrs | geen gegevens | geen gegevens | |
| Senior VP & General Counsel | less than a year | geen gegevens | geen gegevens | |
| Vice President & Head of Human Resources | less than a year | geen gegevens | geen gegevens | |
| Chief of Staff & Clinical Development | 2.7yrs | geen gegevens | geen gegevens | |
| Chief Business Officer | less than a year | geen gegevens | geen gegevens |
2.0yrs
Gemiddelde duur
57yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van IDYA wordt beschouwd als ervaren (gemiddelde ambtstermijn 2 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 9.4yrs | US$6.00m | 0.78% $ 20.6m | |
| Independent Director | 4.9yrs | US$358.02k | 0% $ 0 | |
| Independent Director | 9.1yrs | US$363.02k | 0.0050% $ 130.1k | |
| Independent Director | 3.8yrs | US$349.52k | 0% $ 0 | |
| Chair of Scientific Advisory Board | 5.8yrs | geen gegevens | geen gegevens | |
| Independent Director | 6.3yrs | US$364.52k | 0% $ 0 | |
| Independent Director | 2.6yrs | US$350.52k | 0% $ 0 | |
| Member of Scientific Advisory Board | 8.5yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 5.8yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 8.5yrs | geen gegevens | geen gegevens | |
| Independent Chairman of the Board | 8.8yrs | US$369.52k | 0.019% $ 497.0k | |
| Independent Director | 4.4yrs | US$349.52k | 0% $ 0 |
6.0yrs
Gemiddelde duur
67.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van IDYA wordt beschouwd als ervaren (gemiddelde ambtstermijn 6 jaar).